The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Registration is now officially open for the Fourteenth Annual Meeting of the Society of Hematologic Oncology. The event is scheduled.
How one patient traveled to China to pursue an experimental therapy that changed what was possible in multiple myeloma.
Gwen Nichols, MD, chief medical officer of Blood Cancer United, discusses generational financial toxicity in oncology, particularly in pediatric acute leukemia care, and the critical
In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase,
Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses the ASH 2025 abstract titled, “Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study.”
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm, according to the results of a phase 2 trial presented during the 67th American Society of Hematology Annual Meeting and Exposition.
To access the SOHO Career Center click the following link.
